The NH-BMT and Leukemia Programs are committed to publishing in the field of blood and marrow transplantation, Leukemia and hematologic malignancies. The following publications/presentations demonstrate this commitment.

ASH Oral and Poster Presentations: 2020

Collaborative Oral Presentations:

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings, Jacqueline S. Garcia, MD1, Yael Flamand, MS2*, Benjamin K. Tomlinson, MD3, Michael Keng, MD4*, Lourdes M. Mendez, MD, PhD5, Samer Khaled, MD6, Asad Bashey, MD, PhD7, Andrew M. Brunner, MD8, Alexandra Savell, BS1*, Donna Neuberg9*, Ilene Galinsky10*, Marlise R. Luskin, MD11, David P. Steensma, MD1, Martha Wadleigh, MD10*, Eric S. Winer, MD10, David E. Avigan, MD12, Nicole Cullen11*, Scott Rodig, MD, PhD13,14, Livius Penter1*, R. Coleman Lindsley, MD, PhD1, Stephanie Andrews11*, Matthew S. Davids, MD1, Catherine J. Wu, MD1, Richard M. Stone, MD10, Daniel J. DeAngelo, MD, PhD15 and Robert J. Soiffer, MD16

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study, Farhad Ravandi, MBBS1, Asad Bashey, MD, PhD2, Wendy Stock, MD3, James M. Foran, MD4, Raya Mawad, MD5*, Daniel Egan, MD6*, William Blum, MD7*, Allen Yang, MD, PhD8, Alessandro Pastore, MD9, Chelsea Johnson, BSN, RN8*, Shuo Zheng8*, Musa Yilmaz, MD10 and Alice S. Mims, MD11

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens, Mahasweta Gooptu, MD1, Andrew St. Martin, MS2*, Rizwan Romee, MD3, Mukta Arora, MD4, Monzr M. Al Malki, MD5, Joseph H. Antin, MD3, Christopher Bredeson, MD, FRCPC, MSc6, Claudio G. Brunstein, MD, PhD4, Saurabh Chhabra, MD7, Ephraim J. Fuchs, MD, MBA8, Nilanjan Ghosh, MD, PhD9, Michael R. Grunwald, MD9, Yoshihiro Inamoto, MD10, Christopher G. Kanakry, MD11*, Natasha Kekre, MD, MPH, FRCPC6, Joseph P. McGuirk, DO12, Ian K. McNiece, PhD13*, Rohtesh S. Mehta, MD, MPH, MS14, Marco Last Mielcarek, MD15*, Filipo Milano, MD, PhD16, Dipenkumar Modi, MD17, Ran Reshef, MD18, Mark A. Schroeder, MD19, Robert J. Soiffer, MD3, Scott R. Solomon, MD20, Edmund K. Waller, PhD, MD21 and Mary Eapen, MBBS, MS22

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001, Maria Lia Palomba, MD1, Leo I. Gordon, MD2, Tanya Siddiqi, MD3*, Jeremy S. Abramson, MD4*, Manali Kamdar, MD5*, Matthew A. Lunning, DO, FACP6, David G. Maloney, MD, PhD7, Charalambos Andreadis, MD, MSCE8*, Jon E. Arnason, MD9, Nilanjan Ghosh, MD, PhD10, Amitkumar Mehta, MD11, Scott R. Solomon, MD12, Thalia Farazi, MD, PhD13*, Jacob Garcia, MD13*, Christine Dehner, BSc13*, Ken Ogasawara, PhD, MPH14*, Jie Gao, PhD14* and Michael Wang, MD15

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), William G. Wierda, MD, PhD1, Kathleen A. Dorritie, MD2, Javier Munoz, MD3, Deborah M. Stephens, DO4, Scott R. Solomon, MD5, Heidi H. Gillenwater, MD6*, Lucy Gong, PharmD6*, Lin Yang, PhD6*, Ken Ogasawara, PhD, MPH7*, Jerill Thorpe, BS6* and Tanya Siddiqi, MD8*

Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders,  Jeffrey E. Lancet, MD1, Geoffrey L Uy, MD2, Laura F. Newell, MD3, Tara Lin, MD4, Donna E. Hogge5*, Scott R. Solomon, MD6, Gary J. Schiller, MD7, Matthew J. Wieduwilt, MD, PhD8, Daniel H. Ryan9, Stefan Faderl10, Yu-Lin Chang10* and Jorge E. Cortes, MD11,12

Poster Presentations:

CD34+ Selected Hematopoietic Cell Boosts (HCB) for Treatment of Refractory Cytopenia Following T-Replete HLA-Haploidentical Transplantation,  Asad Bashey, MD, PhD1, Xu Zhang, PhD2*, Lawrence E Morris, MD1, H. Kent Holland, MD1, Scott R. Solomon, MD3 and Melhem Solh, MD1

Collaborative Poster Presentations:

Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience, Siddharth Jayant Kunte, MD1, Lisa Rybicki, MS2*, Auro Viswabandya, MD3, Asad Bashey, MD, PhD4, Madiha Iqbal, MBBS5, Michael R. Grunwald, MD6, Bhagirathbhai Dholaria, MBBS7, Hany Elmariah, MD, MS8, Michael Ozga, MD9, Anurag K. Singh, MD10, Sameem Abedin, MD11, Vikas Gupta, MD, FRCP, FRCPath12, Amy E. DeZern, MD13, Richard J. Jones, MD13, Aaron T. Gerds, MD, MS14 and Tania Jain, MD15

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), Alexander M. Lesokhin, MD1, Moshe Y. Levy, MD2, Andrew P. Dalovisio, MD3, Nizar Bahlis, MD4, Melhem Solh, MD5, Michael Sebag, MD, PhD, FRCPC6, Andrzej Jakubowiak, MD, PhD7, Yogesh S. Jethava, MBBS, MD, FRCPath, MRCP8, Caitlin L. Costello, MD9, Michael P. Chu, MD10, Michael R. Savona, MD11, Cristina Gasparetto, MD12, Suzanne Trudel, MD, MSC, FRCPC13, Jeffrey Chou, MD, PhD14*, Chandrasekhar Udata, PhD15*, Cynthia Basu, PhD15*, Heike I. Krupka, PhD, PMP14* and Noopur S. Raje, MD16

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Paolo F Caimi1*, Weiyun Z. Ai2, Juan Pablo Alderuccio, MD3, Kirit M. Ardeshna4, Mehdi Hamadani, MD5, Brian T. Hess, MD6, Brad S. Kahl, MD7, John A. Radford, MD, FMedSci8*, Melhem Solh, MD9, Anastasios Stathis, MD10*, Pier Luigi Zinzani, MD11, Jay Feingold12*, David Ungar13, Yajuan Qin13*, Shui He13* and Carmelo Carlo-Stella, MD14

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome, Alice S. Mims, MD1, Melhem Solh, MD2, Uma Borate3, Naveen Pemmaraju, MD4, Gautam Borthakur, MD5, Gail J. Roboz, MD6, Ben Powell, PhD7*, Paul Severson, PhD7*, Bernice Matusow7*, Jason Halladay, PhD7*, Ching Hsu, PhD8*, Paul Watkins7*, Chao Zhang, PhD7*, Jackie M. Walling, PhD, MD7, Athanasios C. Tsiatis, MD7 and Amy E. DeZern, MD9

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching, Ephraim J. Fuchs, MD, MBA1, Shannon R McCurdy, MD2*, Scott R. Solomon, MD3, Tao Wang, PhD4*, Michelle Kuxhausen, MS5*, Yvette L Kasamon, MD1*, MHD Monzr Al Malki, MD6, Shahinaz Gadalla, MD, PhD7*, Sophie Paczesny, MD, PhD8, Steven GE Marsh, BSc, PhD, ARCS9*, Bronwen E. Shaw, PhD, MRCP, FRCPath10, Stephen R. Spellman, MS11*, Stephanie J. Lee, MD, MPH11,12 and Effie Petersdorf, MD13*

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial, Andrea Massimiliano Tomirotti, PhD1*, Daniela Bellarosa2*, Scott R. Solomon, MD3, Aziz Nazha, MD4, Stephen A Strickland, MD, MSCI5, Roland P Walter, MD PhD6, Farhad Ravandi, MBBS7, Krzysztof Brzózka, PhD8, Milena Mazan, PhD9*, Simone Baldini, MD10*, Massimiliano Salerno11*, Monica Binaschi, PhD12*, Dirk Laurent, MD13* and Andrea Pellacani, PhD, MD14*

2020 Translation and Cellular Therapy Tandem Meeting:

Extracorporeal Photopheresis (ECP) Improves Overall Survival in the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease (SR aGVHD), ABSTRACT #17687